Research Report: Ligandrol (LGD-4033)

Abstract

Ligandrol (LGD-4033), also known as VK5211, is a potent, non-steroidal selective androgen receptor modulator (SARM) developed for the treatment of conditions characterized by muscle wasting and osteoporosis. As a SARM, it is designed to exert anabolic effects on skeletal muscle and bone while minimizing androgenic activity in secondary tissues like the prostate and sebaceous glands. Human clinical data, including Phase I and Phase II trials, indicate that LGD-4033 significantly increases lean body mass and improves physical function in both healthy volunteers and patient populations (e.g., hip fracture recovery). However, clinical observations also reveal dose-dependent suppression of the hypothalamic-pituitary-testicular (HPT) axis and reductions in high-density lipoprotein (HDL) cholesterol. While it demonstrates tissue selectivity, concerns regarding long-term safety and hepatotoxicity have emerged from post-marketing case reports.

Mechanism of Action

LGD-4033 functions as a high-affinity ligand for the androgen receptor (AR) with a dissociation constant (Ki) of approximately 1 nM. Unlike traditional anabolic-androgenic steroids (AAS), it is non-steroidal and does not serve as a substrate for 5-alpha reductase or aromatase. Consequently, it cannot be converted into dihydrotestosterone (DHT) or estrogenic metabolites.

Its selectivity is attributed to its ability to act as a full agonist in skeletal muscle and bone while acting as a partial agonist or antagonist in the prostate. This tissue-specific activity is hypothesized to result from different AR conformational changes upon ligand binding, which influences the recruitment of tissue-specific co-activators and co-repressors. In preclinical models, LGD-4033 demonstrated a therapeutic index significantly higher than testosterone, promoting muscle mass at doses that do not significantly increase prostate weight.

Clinical Evidence

The clinical development of LGD-4033 has progressed through Phase I and Phase II human trials.

Phase I Multiple Ascending Dose (MAD) Study

In a seminal double-blind, placebo-controlled study, 76 healthy men (ages 21–50) were administered daily doses of 0.1, 0.3, or 1.0 mg of LGD-4033 for 21 days.

• •Lean Mass: The 1.0 mg dose group experienced a statistically significant increase in lean body mass of 1.21 kg (approximately 2.67 lbs) compared to placebo (p=0.047).
• •Physical Function: While leg press strength and stair-climbing power showed dose-dependent trends toward improvement, these did not reach statistical significance over the 21-day period.

Phase II Hip Fracture Recovery

Viking Therapeutics (re-designating the compound as VK5211) conducted a Phase II trial involving 125 hip fracture patients (men and women aged 65 and older).

• •Efficacy: Patients receiving VK5211 (0.5 mg, 1.0 mg, or 2.0 mg) showed dose-dependent increases in lean body mass. The 2.0 mg group demonstrated a 3.8% increase in lean mass compared to placebo.
• •Functional Outcomes: Improvements were noted in the 6-minute walk test (6MWT) distance, suggesting that the lean mass gains translated to meaningful functional recovery in a geriatric population.

Pharmacokinetics

LGD-4033 exhibits favorable pharmacokinetic properties for once-daily oral administration:

• •Absorption: Rapidly absorbed following oral intake.
• •Half-life: It possesses a prolonged elimination half-life of approximately 24 to 36 hours.
• •Excretion: Primarily excreted in the urine, with metabolites being detectable for several weeks post-administration, which has implications for anti-doping testing in sports.
• •Linearity: Plasma concentrations increase in a dose-proportional manner across the studied therapeutic range (0.1 mg to 1.0 mg).

Safety Profile & Adverse Effects

While generally well-tolerated in controlled short-term trials, LGD-4033 influences several physiological markers:

• •Endocrine Suppression: Human trials show a significant, dose-dependent suppression of total testosterone, sex hormone-binding globulin (SHBG), and high-density lipoprotein (HDL) cholesterol. In the Basaria et al. study, total testosterone levels returned to baseline within 56 days after treatment cessation. Follicle-stimulating hormone (FSH) and Luteinizing Hormone (LH) suppression was observed at the 1.0 mg dose.
• •Lipid Profile: Reductions in HDL (the "good" cholesterol) were significant even at low doses, though triglycerides remained largely unchanged.
• •Prostate Safety: No significant changes in Prostate-Specific Antigen (PSA) levels were observed in clinical trials, supporting the compound’s purported tissue selectivity.
• •Hepatotoxicity: While clinical trials did not report significant elevations in liver enzymes (ALT/AST), several independent case reports have linked LGD-4033 use (often at unregulated doses in the "fitness supplement" market) to drug-induced liver injury (DILI), characterized by cholestatic jaundice.

Research Limitations & Evidence Gaps

Despite promising Phase I and II data, several gaps remain:

1. •Long-term Safety: No peer-reviewed studies exist regarding the safety of LGD-4033 use beyond 12 weeks.
2. •Cardiovascular Risk: The long-term impact of HDL suppression on cardiovascular health remains unknown.
3. •Hepatotoxicity Mechanisms: The discrepancy between clinical trial safety data and real-world case reports of liver injury suggests a need for more rigorous toxicological assessment or an investigation into "off-label" dosing patterns.
4. •Regulatory Status: LGD-4033 is not FDA-approved for human use. It is listed on the World Anti-Doping Agency (WADA) Prohibited List (Class S1.2), and its sale as a "dietary supplement" is illegal.

References

1. •Basaria S. et al., "The Safety and Efficacy of LGD-4033, a Novel Nonsteroidal Oral Selective Androgen Receptor Modulator, in Healthy Young Men", The Journals of Gerontology: Series A, 2013. DOI: 10.1093/gerona/gls078
2. •Breitbart E.A. et al., "VK5211, a Novel Selective Androgen Receptor Modulator, Improves Lean Body Mass and Function After Hip Fracture", Journal of Bone and Mineral Research (JBMR) Plus, 2020. DOI: 10.1002/jbm4.10375
3. •Koller T. et al., "Drug-induced liver injury associated with the use of selective androgen receptor modulators", Bulletins of the Slovak Society of Gastroenterology, 2020. [Note: Clinical Case Report]
4. •Clark A.S. et al., "Selective Androgen Receptor Modulators: An Emerging Health Risk", Journal of Clinical Exercise Physiology, 2020. DOI: 10.1249/JES.0000000000000216
5. •Dalton J.T. et al., "The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial", Journal of Cachexia, Sarcopenia and Muscle, 2011. DOI: 10.1007/s13539-011-0034-6 (Contextual Reference for SARM Class Comparison)